Full HA Protocol - Clinical Guidelines

🚨 IN AN EMERGENCY? CLICK HERE FOR THE QUICK-ACTION CHEAT SHEET

Comprehensive Protocol for Dermal Filler Vascular Occlusion Management

CRITICAL DIRECTIVE: Immediate recognition and high-dose pulsed hyaluronidase (1500 IU every 15-20 minutes) are the cornerstones of treatment. Intervention within 4-6 hours significantly improves outcomes—early-stage ischemia is reversible in up to 80% of cases.

1. Clinical Recognition

Pain and skin color changes are the most prevalent early signs of vascular occlusion. The frontonasal and angulonasal territories are most commonly affected, involving the facial artery (58%) and ophthalmic artery (48%) angiosomes.

Progression of Ischemia

2. Immediate Treatment Protocol (Hyaluronic Acid Fillers)

Hyaluronidase Administration

• Initial dose: Inject 1500 IU immediately into and around the affected area.
• Frequency: Repeat every 15-20 minutes until perfusion improves. Animal studies show repeated pulsed dosing is superior to a single high dose.
• Duration: Continue treatment until clinical improvement is evident (typically within 60 minutes).
• Testing: No skin testing is required in emergency situations.
• Guidance: Ultrasound guidance can reduce required doses by up to tenfold.

Adjunctive Pharmacotherapy

• Aspirin: 325 mg orally to prevent platelet aggregation and further clot formation.
• Corticosteroids: Administer to control the inflammatory response.
• Warm Compresses: Apply to aid vasodilation.
• Massage: Perform vigorous massage of the affected area.

Advanced Interventions

• Ultrasound-Guided Targeted Injection: Allows precise localization of filler deposits, significantly reducing the total hyaluronidase dose needed while improving outcomes.
• Intraarterial Hyaluronidase: For severe cases with extensive necrosis or when standard treatment fails. Percutaneous intraarterial injection of 1500 IU via the facial or supratrochlear artery has shown excellent efficacy (94% complete healing in severe cases).
• Hyperbaric Oxygen Therapy (HBOT): Enhances tissue oxygenation and supports ischemic recovery; particularly beneficial for established necrosis.

3. Wound Management (Stage 3+ Ischemia)

If necrosis develops and tissue breaks down, implement the following:

• Debridement of necrotic tissue.
• Application of Platelet-rich fibrin (iPRF/sPRF) to the wound surface.
• Nanofat grafting for tissue regeneration.
• Consideration of botulinum toxin to reduce metabolic demand in ischemic tissue.

4. Critical Timing Considerations

• Within 6 hours: Significantly improves outcomes (78.4% resolution rate for skin necrosis).
• Within 24 hours: Typically prevents permanent sequelae.
• Beyond 24 hours: Prognosis deteriorates significantly.

5. Contraindications (What NOT to Do)

• Do NOT use Nitroglycerin Paste: Current evidence reserves vasodilators for post-resolution perfusion improvement only, not acute management.
• Do NOT use Sodium Thiosulfate: This lacks evidence for filler occlusion and should not be used.

6. NON-HA FILLERS: Biostimulators & Structural Fillers

Important Disclaimer: This primary protocol is specifically designed for the management of vascular occlusion secondary to Hyaluronic Acid (HA) dermal fillers.

If occlusion occurs with non-HA biostimulators or structural fillers (e.g., calcium hydroxylapatite, poly-L-lactic acid), hyaluronidase will not dissolve the product.

• Flooding the area with high-dose hyaluronidase may still be utilized to help disperse localized pressure and reduce interstitial edema.
• In non-HA cases, the primary focus must immediately shift to maximizing vasodilation, hyperbaric oxygen therapy (HBOT), and immediate expert consultation.

7. Emergency Preparedness & Clinical Management

The "Filler Crash Cart"

Every clinic must maintain an immediately accessible crash cart containing:

• Multiple vials of hyaluronidase (minimum 3000-4500 IU reconstituted or ready to mix)
• Aspirin (325 mg)
• Warm compresses
• Corticosteroids
• Emergency contact information for an on-call ophthalmologist

SPECIAL CONSIDERATION: Ocular Involvement

If cutaneous involvement extends to the ophthalmic angiosome territory, there is a 39% risk of vision loss (compared to 0.8% without ophthalmic involvement). Immediate ophthalmology consultation is mandatory. Retinal artery occlusion requires emergent intraarterial or retrobulbar hyaluronidase.

Clinical Documentation Requirements

Thorough documentation during a high-stress vascular occlusion event is easily overlooked but critical for patient continuity of care and medico-legal protection. If possible, immediately assign a secondary staff member to act as the dedicated "scribe" during the event.

• Baseline Photography: Capture clear, well-lit photos of the affected area and surrounding tissues explicitly before administering the first hyaluronidase injection.
• Serial Photography: Take progress photos every 15-20 minutes prior to each new round of injections to objectively document changes in capillary refill, livedo reticularis, and tissue color.
• Event Log: Document the exact time of symptom onset, specific clinical signs observed by the provider, and the anatomical location of the suspected occlusion.
• Dosing Log: Record the exact time, exact dosage (in IU), and anatomical placement of every single hyaluronidase injection administered.
• Patient Communication: Document ongoing communication with the patient, including their continuously reported pain levels, vision checks, and verbal consent to the emergency treatment plan.

8. Anaphylaxis Management Protocol

The administration of high-dose, repeated hyaluronidase carries an inherent risk of severe allergic reaction or anaphylaxis. Practitioners must be prepared to pivot immediately from occlusion management to anaphylaxis management if systemic symptoms appear.

Clinical Signs of Anaphylaxis:

• Sudden onset of widespread hives, erythema, or severe pruritus
• Respiratory distress, wheezing, shortness of breath, or stridor
• Hypotension, dizziness, tachycardia, or loss of consciousness
• Rapid swelling of the tongue, uvula, lips, or airway

Immediate Action Steps:

1. First Line: Administer Epinephrine (0.3 mg intramuscularly in the anterolateral thigh) immediately. Do not delay.
2. Emergency Response: Call emergency medical services immediately.
3. Positioning: Place the patient in a supine position with legs elevated to maximize perfusion to vital organs (unless breathing is severely impaired, in which case allow them to sit up).
4. Secondary Meds: Administer adjunctive H1/H2 antihistamines (e.g., diphenhydramine) and systemic corticosteroids only after epinephrine has been given and the airway is secure.

References

• Madero-Pérez J, Gil-Martinez M, Muñoz-Gonzalez C, et al. Guide for Managing Vascular Occlusion Caused by Fillers With Exclusive Cutaneous Involvement: A Review of Diagnosis, Classification, and Treatment. Aesthetic Plastic Surgery. 2026;50(5):2068-2082.
• Alhusain AM, Alsaif M, Alkhathami AM, et al. Hyaluronidase Protocol in Management of Hyaluronic Acid Filler-Related Vascular Complications: A Systematic Review and Meta-Analysis. Aesthetic Plastic Surgery. 2026;50(6):2300-2317.
• DeLorenzi C. Complications of Injectable Fillers, Part 2: Vascular Complications. Aesthetic Surgery Journal. 2014;34(4):584-600.
• Yi KH. Understanding Vascular Complications Arising From Dermal Filler Injection. The Journal of Craniofacial Surgery. 2025;36(4):1168-1174.
• Soares DJ, Bowhay A, Blevins LW, Patel SM, Zuliani GF. Patterns of Filler-Induced Facial Skin Ischemia: A Systematic Review of 243 Cases and Introduction of the FOEM Scoring System and Grading Scale. Plastic and Reconstructive Surgery. 2023;151(4):592e-608e.
• Lee W, Oh W, Oh SM, Yang EJ. Comparative Effectiveness of Different Interventions of Perivascular Hyaluronidase. Plastic and Reconstructive Surgery. 2020;145(4):957-964.
• Cohen JL, Biesman BS, Dayan SH, et al. Treatment of Hyaluronic Acid Filler-Induced Impending Necrosis With Hyaluronidase: Consensus Recommendations. Aesthetic Surgery Journal. 2015;35(7):844-9.
• Zheng C, Fu Q, Zhou GW, et al. Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection. Aesthetic Surgery Journal. 2022;42(6):649-655.
• Nazari S, Fakih-Gomez N, Hadadian N, et al. A New Protocol (THIS and FAT) for the Treatment of Filler-Induced Vascular Occlusion: A Case Series. Frontiers in Medicine. 2025;12:1585983.
• Al-Alam Sansur S, Destang D. Use of the High-Dose Pulsed Hyaluronidase Protocol in the Management of Impending Skin Necrosis Associated With Hyaluronic Acid Fillers: A Systematic Review. International Journal of Oral and Maxillofacial Surgery. 2023;52(1):79-87.
• Loyal J, Hartman N, Fabi SG, Butterwick KJ, Goldman MP. Cutaneous Vascular Compromise and Resolution of Skin Barrier Breakdown After Dermal Filler Occlusion-Implementation of Evidence-Based Recommendations Into Real-World Clinical Practice. Dermatologic Surgery. 2022;48(6):659-663.